Jefferies raised the firm’s price target on Roche to CHF 250 from CHF 240 and keeps a Hold rating on the shares. First half sales should meet consensus, though the firm’s forecasted profits are 3%-5% below consensus, the analyst tells investors in a preview note for the EU pharma group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)
- CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition
- Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection
- Halozyme: Roche’s OCREVUS SC with ENHANZE receives EC approval
- Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis